We're delighted to announce our participation at ISPOR Europe 2024 in Barcelona this November. We'll...
Read moreThis study examines how Advanced Therapy Medicinal Products (ATMPs) demonstrate economic benefit for...
Read moreNICE recommends gene therapy for severe beta-thalassaemia, offering hope for improved quality of lif...
Read moreNew ground-breaking gene therapy for haemophilia B enters NHS England's Innovative Medicines Fund, o...
Read moreNICE recommends Kymriah® for routine NHS use, offering immense benefits for those with resistant B-...
Read moreWe explore CAR T-cell therapy challenges, regulatory approvals, market growth, pricing models, and a...
Read moreSafety signals have sparked vital discussions on patient access to ATMPs, marking a pivotal moment i...
Read moreObjectives The objective of this study is to explore the role of economic benefit in the HTA decisio...
Read moreBack in January this year, we summarised the key trends our market access experts believed would dom...
Read moreThe MHRA grants conditional approval to Casgevy, the first-ever CRISPR gene-editing therapy for sick...
Read more